Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertrophic Clear all

Conditions: Benign Prostatic Hypertrophy (BPH), Lower Urinary Track Symptoms
Interventions: Survey using a questionnaire.; Other
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Male Urogenital Diseases, Genital Diseases, Male, Prostatic Disease, Prostatic Hyperplasia
Interventions: SoracteLite(TM) TPLA for BPH; Device
Lead sponsor: Urological Research Network, LLC; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Hypertrophic Cardiomyopathy
Interventions: Viz HCM ECG Review, Baseline Effectiveness Cohort; Behavioral
Lead sponsor: Viz.ai, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: La Jolla, California • Ridgewood, New Jersey • New York, New York + 2 more

Conditions: Hypertrophic Cardiomyopathy (HCM)
Interventions: myocardial contrast echo; Diagnostic Test
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Burn
Interventions: 3-Dimensional Color Scanning; Device
Lead sponsor: Legacy Health System; Other
Eligibility: 4 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Heart Failure
Interventions: Paricalcitol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Burn Scars
Interventions: Pulse-Dye Laser, Sham; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 9 Years to 21 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety, Gastrointestinal Hemorrhage, Hepatomegaly, Lymphadenopathy, Macroglossia, Nausea, Primary Systemic Amyloidosis, Purpura, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
Interventions: Isatuximab, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 345
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Burbank, California + 234 more

Conditions: Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects
Interventions: CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Subjects
Interventions: Protein Isolate, Progressive Resistance Exercise Training (PRE); Dietary Supplement · Behavioral
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kidney Failure, Chronic
Interventions: Spironolactone; Drug
Lead sponsor: Dawnmarie DeFazio; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Burn Scar, Hypertrophic Scar, Hyperpigmentation, Hypopigmented Scar
Interventions: Not listed
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: Personalized cardiac pacing; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 40 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 30
States / cities: Phoenix, Arizona • Palo Alto, California • San Francisco, California + 26 more

Conditions: Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy, Cardiac Amyloidosis, Anderson Fabry Disease, Sarcoidosis, Cancer Therapy-related Cardiac Dysfunction, Ventricular Arrythmia, Heart Failure
Interventions: Not listed
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Augmentation, Augmentation Revision, General Breast Enlargement, Post-lactational Involution, Asymmetry
Interventions: Mentor Spectra/Becker 80 Breast Implant; Device
Lead sponsor: Mentor Worldwide, LLC; Industry
Eligibility: 22 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Hypertrophic Cardiomyopathy
Interventions: pacemaker implantation, percutaneous transluminal septal ablation (PTSA); Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertrophic
Interventions: embrace device; Device
Lead sponsor: Neodyne Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hypertrophic Scar
Interventions: OLX10010; Drug
Lead sponsor: Olix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Miami, Florida • Detroit, Michigan + 2 more

Conditions: Keloid Scars, Hypertrophic Scars
Interventions: Cryotherapy with liquid nitrogen, Intralesional Triamcinolone 10 mg/ml; Device · Drug
Lead sponsor: Sonal Choudhary; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertrophic Cardiomyopathy, Hearing Loss, Cancer
Interventions: GeneInsight Clinic (GIC); Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 8
States / cities: Boston, Massachusetts • Ann Arbor, Michigan

Conditions: Fibrosis, Skin Scarring, Skin Wound, Hypertrophic Scar, Scar, Keloid
Interventions: LED-RL phototherapy, Mock irradiation; Device
Lead sponsor: State University of New York - Downstate Medical Center; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Cardiomegaly
Interventions: MEK162; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Erectile Dysfunction
Interventions: Penile Traction Device, Inflatable Penile Prosthesis Implantation; Device · Procedure
Lead sponsor: J. Peter Rubin, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Muscle Fiber Atrophy, Type II
Interventions: Neuromuscular electrical stimulation, voluntary strengthening exercise; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms

Office Based Transperineal Laser Ablation for Benign Prostatic Hyperplasia HYPERPLASIA

Viz HCM (ECG Assist) Utilization Workflow Pilot

Perfusion Abnormalities in Hypertrophic Cardiomyopathy

Hypertrophic Scarring After Facial Burn

The Effects of Active VItamin D on Left Atrial Volume Index

Laser Therapy for Treating Hypertrophic Burn Scars in Children

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

Pea vs Whey Protein Supplementation With Resistance Training on Young Adults' Strength, Body Composition, and Metabolic Parameters

Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease

Characterization of Dyschromic Hypertrophic Scar

ELEVATE-HFpEF Clinical Study

Cardiovascular Multimodality Imaging Study

Spectra Breast Implant Study

A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy

Investigation of a Novel Silicone Dressing to Maximize the Outcomes of Scar Revision Procedures (IMPROVE)

Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery

Topical Cryotherapy and Keloid/Hypertrophic Scars

Refining Information Technology Support for Genetics in Medicine

Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

Penile Lengthening Pre-Penile Prosthesis Implantation

The Effect of Neuromuscular Electrical Stimulation (NMES)